- Email: [email protected]
P1.02-039 Assessment of KRAS mutations (by Digital PCR) in Circulating Tumoral DNA from Lung Adenocarcinoma Patients
January 2017
Conclusion: Serum EGFR1 gene was over expressed by >16 fold in advanced adenocarcinoma lung compared to healthy controls. The association of EGFR expression with other clinical disease characteristics needs further exploration.
Abstracts
S511
of extra-thoracic disease, with bone (2 cases), brain (1 case), and abdominal lymph node (1 case) as the only metastatic location outside the thorax. KRAS clonal dynamics in plasma showed a good correlation with treatment responses in some cases (figure 1).
Keywords: EGFR expression, RT-PCR, adenocarcinoma lung
P1.02-039 Assessment of KRAS mutations (by Digital PCR) in Circulating Tumoral DNA from Lung Adenocarcinoma Patients Topic: Driver Genes in NSCLC, Resistance, and Other Álvaro Taus,1 Laura Camacho,2 Ainhoa Hernández,1 Gabriel Piquer,2 Eva López,1 Alba Dalmases,3 David Casadevall,1 Lara Pijuan,3 Max Hardy,1 Raquel Longarón,3 Pedro Rocha,1 Arnau Zafra,2 Joan Albanell,1 Beatriz Bellosillo,3 Edurne Arriola1 1 Medical Oncology Department, Hospital Del Mar, Barcelona/Spain, 2Imim (Institut Hospital Del Mar D’Investigacions Mèdiques), Barcelona/Spain, 3Pathology Department, Hospital Del Mar, Barcelona/Spain Background: KRAS mutations are detected in approximately 25% of lung adenocarcinomas (LA). Targeted therapies against KRAS are under investigation. The use of tumor biopsy for molecular testing may be challenging due to the invasiveness of the procedure, the limited material for multiple biomarker analyses and tumor heterogeneity. Mutation detection in circulating cell-free tumor DNA (ctDNA) can overcome these caveats and also be used for tracking tumor dynamics. The aim of this study was to evaluate KRAS mutation detection in plasma samples from LA. Methods: Plasma samples from 35 patients with histologically confirmed KRAS mutant LA were collected at initiation of chemotherapy. KRAS mutations were assessed using digital PCR technology (QuantStudio3D Digital PCR System, Thermofisher Scientific). Correlation between ctDNA and tumor biopsies in terms of mutation detection was analyzed. In 5 cases plasma samples were obtained during the course of the disease to monitor clonal dynamics. Results: Most cases were male (71%), with stage IV disease (83%), and showed KRAS mutation on codon12 (94%). KRAS mutation was found in plasma samples in 28/35 cases, showing a concordance with the tumor of 80%. In patients whose disease was limited to thorax (stages II, III, and IVa) KRAS mutation was detected in 7/ 10 (70%) plasma samples. Plasma/tumor biopsy concordance in cases with extra-thoracic metastases was 84% (21/25). The 4 false negative cases had low burden
Conclusion: High concordance in the detection of KRAS mutations was found between plasma and tumor tissue using digital PCR technology, particularly in cases with extra-thoracic disease. Digital PCR allows for tracking clonal dynamics in KRAS mutant LA. Keywords: liquid biopsy, KRAS, Clonal dynamics, lung adenocarcinoma
P1.02-040 Heterogeneity of the EGFR / KRAS Gene Mutation in Multifocal Lung Adenocarcinoma and the Clinical Significance Topic: Driver Genes in NSCLC, Resistance, and Other Lin Li,1 Susu Zhang,2 Hongshuang Dai,2 Jianming Ying,1 Yanning Gao2 1Department of Pathology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing/China, 2State Key Laboratory of Molecular Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing/China Background: Significant advances on EGFR-targeted therapy have allowed increasing availability of therapeutic options for non-small cell lung cancers. For multifocal lung adenocarcinoma patients in clinic, the EGFR gene mutation is generally examined only on the largest tumor or the one containing the most tumor cells, which could omit the tumors harboring the EGFR mutation and thus loss of opportunity for the tyrosine kinase inhibitors therapy.
Conclusion: Serum EGFR1 gene was over expressed by >16 fold in advanced adenocarcinoma lung compared to healthy controls. The association of EGFR expression with other clinical disease characteristics needs further exploration.
Abstracts
S511
of extra-thoracic disease, with bone (2 cases), brain (1 case), and abdominal lymph node (1 case) as the only metastatic location outside the thorax. KRAS clonal dynamics in plasma showed a good correlation with treatment responses in some cases (figure 1).
Keywords: EGFR expression, RT-PCR, adenocarcinoma lung
P1.02-039 Assessment of KRAS mutations (by Digital PCR) in Circulating Tumoral DNA from Lung Adenocarcinoma Patients Topic: Driver Genes in NSCLC, Resistance, and Other Álvaro Taus,1 Laura Camacho,2 Ainhoa Hernández,1 Gabriel Piquer,2 Eva López,1 Alba Dalmases,3 David Casadevall,1 Lara Pijuan,3 Max Hardy,1 Raquel Longarón,3 Pedro Rocha,1 Arnau Zafra,2 Joan Albanell,1 Beatriz Bellosillo,3 Edurne Arriola1 1 Medical Oncology Department, Hospital Del Mar, Barcelona/Spain, 2Imim (Institut Hospital Del Mar D’Investigacions Mèdiques), Barcelona/Spain, 3Pathology Department, Hospital Del Mar, Barcelona/Spain Background: KRAS mutations are detected in approximately 25% of lung adenocarcinomas (LA). Targeted therapies against KRAS are under investigation. The use of tumor biopsy for molecular testing may be challenging due to the invasiveness of the procedure, the limited material for multiple biomarker analyses and tumor heterogeneity. Mutation detection in circulating cell-free tumor DNA (ctDNA) can overcome these caveats and also be used for tracking tumor dynamics. The aim of this study was to evaluate KRAS mutation detection in plasma samples from LA. Methods: Plasma samples from 35 patients with histologically confirmed KRAS mutant LA were collected at initiation of chemotherapy. KRAS mutations were assessed using digital PCR technology (QuantStudio3D Digital PCR System, Thermofisher Scientific). Correlation between ctDNA and tumor biopsies in terms of mutation detection was analyzed. In 5 cases plasma samples were obtained during the course of the disease to monitor clonal dynamics. Results: Most cases were male (71%), with stage IV disease (83%), and showed KRAS mutation on codon12 (94%). KRAS mutation was found in plasma samples in 28/35 cases, showing a concordance with the tumor of 80%. In patients whose disease was limited to thorax (stages II, III, and IVa) KRAS mutation was detected in 7/ 10 (70%) plasma samples. Plasma/tumor biopsy concordance in cases with extra-thoracic metastases was 84% (21/25). The 4 false negative cases had low burden
Conclusion: High concordance in the detection of KRAS mutations was found between plasma and tumor tissue using digital PCR technology, particularly in cases with extra-thoracic disease. Digital PCR allows for tracking clonal dynamics in KRAS mutant LA. Keywords: liquid biopsy, KRAS, Clonal dynamics, lung adenocarcinoma
P1.02-040 Heterogeneity of the EGFR / KRAS Gene Mutation in Multifocal Lung Adenocarcinoma and the Clinical Significance Topic: Driver Genes in NSCLC, Resistance, and Other Lin Li,1 Susu Zhang,2 Hongshuang Dai,2 Jianming Ying,1 Yanning Gao2 1Department of Pathology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing/China, 2State Key Laboratory of Molecular Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing/China Background: Significant advances on EGFR-targeted therapy have allowed increasing availability of therapeutic options for non-small cell lung cancers. For multifocal lung adenocarcinoma patients in clinic, the EGFR gene mutation is generally examined only on the largest tumor or the one containing the most tumor cells, which could omit the tumors harboring the EGFR mutation and thus loss of opportunity for the tyrosine kinase inhibitors therapy.